

- 対する新たな治療戦略, 転移性肝癌に対する化学療法(会議録). 肝臓 2005 ; 46 Suppl 2 : 413.
- 26) Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. *Oncology* 2000 ; 58(3) : 191-7.
- 27) Baba H, Yamamoto M, Endo K, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. *Gastric Cancer* 2003 ; 6 Suppl 1 : 45-9.
- 28) Tsuji A, Morita S, Shima Y, et al. Phase II study of CDDP+S-1 combination chemotherapy for advanced and recurrent gastric cancer. *Proc ASCO* 2004. #4148.
- 29) Yoshida K, Hirabayashi N, Takiyama W, et al. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. *Anticancer Res* 2004 ; 24(3b) : 1843-51.
- 30) Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. *J Clin Oncol* 1999 ; 17(1) : 319-23.
- 31) Kumada T, Arai Y, Itoh K, et al. Phase II study of combined administration of 5-fluorouracil, epirubicin and mitomycin-C by hepatic artery infusion in patients with liver metastases of gastric cancer. *Oncology* 1999 ; 57(3) : 216-23.
- 32) Arai Y, Sone Y, Inaba Y, et al. Hepatic arterial infusion chemotherapy for liver metastases from breast cancer. *Cancer Chemother Pharmacol* 1994 ; 33 Suppl : S142-4.
- 33) Yonemura Y, Matuki N, Sakuma H, et al. Effect of intra-hepatoarterial infusion of MMC and CDDP for gastric cancer patients with liver metastases. *Surg Today* 1992 ; 22(3) : 253-9.
- 34) Takahashi H, Tono T, Tamagaki S, et al. Usefulness of hepatic arterial infusion chemotherapy for liver metastasis in gastric cancer. *Gan To Kagaku Ryoho* 2001 ; 28(11) : 1724-7.
- 35) 井俣孝司, 大川智久. DSM動注化学療法が奏効し切除し得た胃癌肝転移の2例. *Radiology Frontier* (1344-316X) 2004 ; 7(2) : 150-2.
- 36) Man C Fung, 高山史真子, 石黒 洋, ほか. 進行性・転移性膵癌に対する化学療法—30年間にわたる43ランダム化比較臨床試験の分析(1974~2002年)—. *癌と化学療法* 2003 ; 30(8) : 1101-11.
- 37) Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. *J Clin Oncol* 1997 ; 15(6) : 2403-13.
- 38) Reni M, Cordio S, Milandri C, et al. Related Articles, Links Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer : a randomised controlled multicentre phase III trial. *Lancet Oncol* 2005 ; 6(6) : 369-76.
- 39) Moore MJ, Goldstein D, Hamn J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Groups (NCIC-CTG) [abstract]. *Proc ASCO* 2005 ; 23 : 1.
- 40) Funakoshi A, Okusaka T, Ishii H, et al. Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer [abstract]. *Proc ASCO* 2004. #4102.
- 41) Furuse J, Okusaka T, Funakoshi A, et al. A phase II study of S-1 in patients with metastatic pancreatic cancer [abstract]. *Proc ASCO* 2005. #4104.
- 42) Tsuji A, Morita S, Horimi T, et al. A phase II study of 5-FU (CVI) and low-dose consecutive CDDP (LFP) therapy in advanced pancreatic cancer. *Proc ASCO* 2002. #628.
- 43) 本間久登, 新津洋司郎. 切除不能膵癌に対する新たな動注化学療法. *癌と化学療法* 2002 ; 29(3) : 383-9.
- 44) 三浦靖彦, 上田倫夫, 国広 理, ほか. 膵癌に対する肝動注療法. *癌と化学療法* 2004 ; 31(2) : 195-8.

* * *

レジメン一覧

高知医療センターにおける実際の化学療法

- | | |
|------------------------|---------------------------|
| 1. FP療法 | 11. low-dose FP(LFP)療法 |
| 2. DCF療法 | 12. CPT-11療法 |
| 3. FOLFIRI療法 | 13. CPT-11/CDDP療法 |
| 4. FOLFOX4療法 | 14. CPT-11/CDDP24時間持続静注療法 |
| 5. mFOLFOX6療法 | 15. CPT-11 24時間持続静注療法 |
| 6. mFOLFOX7療法 | 16. weeklyPTX療法(点滴前処置) |
| 7. PEFG療法 | 17. DTX療法(前処置あり) |
| 8. S-1/CDDP療法 | 18. CPT-11/LV/FU(IFL)療法 |
| 9. low-dose CDDP+S-1療法 | 19. LV/FU(RPMI)療法 |
| 10. WHF肝動注療法 | |

注意すべき有害事象 血：血液毒性 消：消化器毒性 腎：腎毒性 神：神経毒性 倦：倦怠感 脱：脱毛
--

1. FP療法

day 1, 2, 3, 4, 5/28

注意点 腎 血 消

投与順	投与薬剤	投与量	投与法
day1	1 ナゼア注0.3mg 2 mL ブドウ糖注 5 %20mL	0.3 mg 20 mL	ワンショット静脈注射
	2 ガスター注20mg 生理食塩液20mL	20 mg 20 mL	ワンショット静脈注射
	3 ポララミン注 5 mg 1 mL ブドウ糖注 5 %100mL	5 mg 100 mL	点滴静注 0.5時間
	4 デカドロン注 8 mg 2 mL ブドウ糖注 5 %100mL	12 mg 100 mL	点滴静注 0.5時間
	5 ランダ注50mg100mL 生理食塩液 1 L	80(-100) mg/m ² 1000 mL	点滴静注 2時間 遮光
	6 マンニトール注20%300mL	300 mL	点滴静注 2時間
	7 5-FU注250mg 5 mL 注射用水20mL	800(-1000) mg/m ² 5-FU注と合計45 mL	中心静脈(埋込型カテーテル) バクスター シングルデイインフューザー使用 22時間
day2	1 ナゼア注0.3mg 2 mL ブドウ糖注 5 %20mL	0.3 mg 20 mL	ワンショット静脈注射
	2 デカドロン注 8 mg 2 mL ブドウ糖注 5 %100mL	12 mg 100 mL	点滴静注 0.5時間
	3 5-FU注250mg 5 mL 注射用水20mL	750 mg/m ² 5-FU注と合計49 mL	中心静脈(埋込型カテーテル) バクスター シングルデイインフューザー使用 24時間
day3, 4, 5	1 5-FU注250mg 5 mL 注射用水20mL	750 mg/m ² 5-FU注と合計49 mL	中心静脈(埋込型カテーテル) バクスター シングルデイインフューザー使用 24時間

原法(CF療法)：シスプラチン注100mg/m² 1-3時間点滴(d1), 5-FU注 1,000mg/m²/日の持続点滴 5日間.
これを4週間毎に繰り返す.

day1 : 1, 4 および day2 : 1, 2 は有害事象に対する前投薬(推奨).

day1 : 2, 3 はアレルギー予防, 必須ではない.

在宅化学療法加算1500点+携帯型ポンプ加算2500点算定可.

CDDPはClイオン存在下でないと不安定となるので生理食塩水で希釈.

アミノ酸製剤等と混注しないこと. CDDP投与中は他の薬剤を一時休止が望ましい.

DTXは添付の溶解液中にアルコールを含有するため注意が必要.

終了後自己抜針.

day1 : インフューザー総量45ml = 2 ml/h × 22時間(44ml) + ポンプに残る量(1 ml)

day2-5 : インフューザー総量49ml = 2 ml/h × 24時間(48ml) + ポンプに残る量(1 ml)

2. DCF療法

day 1, 2, 3, 4, 5/21

注意点 腎 血 消

投与順	投与薬剤	投与量	投与法
day1	1 ナゼア注0.3mg 2 mL ブドウ糖注 5 %20mL	0.3 mg 20 mL	ワンショット静脈注射
	2 ガスター注20mg 生理食塩液20mL	20 mg 20 mL	ワンショット静脈注射
	3 ポララミン注 5 mg 1 mL ブドウ糖注 5 %100mL	5 mg 100 mL	点滴静注 0.5時間
	4 デカドロン注 8 mg 2 mL ブドウ糖注 5 %100mL	12 mg 100 mL	点滴静注 0.5時間
	5 ドセタキセル注80mg 2 mL<溶解液付> 生理食塩液250mL	60(-75) mg/m ² 250 mL	点滴静注 1時間
	6 ランダ注50mg100mL 生理食塩液 1 L	60(-75) mg/m ² 1000 mL	点滴静注 2時間
	7 マンニトール注20%300mL	300 mL	遮光 点滴静注 2時間
	8 5-FU注250mg 5 mL 注射用水20mL	750 mg/m ² 5-FU注と合計45 mL	中心静脈(埋込型カテーテル) バクスター シングルデイインフューザー使用 22時間
day2	1 ナゼア注0.3mg 2 mL ブドウ糖注 5 %20mL	0.3 mg 20 mL	ワンショット静脈注射
	2 デカドロン注 8 mg 2 mL ブドウ糖注 5 %100mL	12 mg 100 mL	点滴静注 0.5時間
	3 5-FU注250mg 5 mL 注射用水20mL	750 mg/m ² 5-FU注と合計49 mL	中心静脈(埋込型カテーテル) バクスター シングルデイインフューザー使用 24時間
day3, 4, 5	1 5-FU注250mg 5 mL 注射用水20mL	750 mg/m ² 5-FU注と合計49 mL	中心静脈(埋込型カテーテル) バクスター シングルデイインフューザー使用 24時間

原法(TCF療法)：ドセタキセル注75mg/m² 1時間点滴(d1), シスプラチン注75mg/m² 1-3時間点滴(d1), 5-FU 750mg/m²/日の持続点滴 5日間。これを3週間毎に繰り返す。

day1: 1, 4 および day2: 1, 2 は有害事象に対する前投薬(推奨)。

day1: 2, 3 はアレルギー予防, 必須ではない。

在宅化学療法加算1500点+携帯型ポンプ加算2500点算定可。

CDDPはClイオン存在下でない不安定となるので生理食塩水で希釈。

アミノ酸製剤等と混注しないこと。CDDP投与中は他の薬剤を一時休止が望ましい。

DTXは添付の溶解液中にアルコールを含有するため注意が必要。

終了後自己抜針。

day1: インフューザー総量45ml=2 ml/h×22時間(44ml)+ポンプに残る量(1 ml)

day2-5: インフューザー総量49ml=2 ml/h×24時間(48ml)+ポンプに残る量(1 ml)

3. FOLFIRI療法

day 1,2/14

注意点 消 血 脱

投与順	投与薬剤	投与量	投与法
day1	1 ナゼア注0.3mg 2 mL ブドウ糖注 5 %20mL	0.3 mg 20 mL	ワンショット静脈注射
	2 デカドロン注 8 mg 2 mL ブドウ糖注 5 %100mL	8 mg 100 mL	点滴静注 0.5時間
	3 アイソボリン注25mg ブドウ糖注 5 %250mL	200 mg/m ² 250 mL	点滴静注 2時間
	4 トポテシン注100mg 5 mL 生理食塩液250mL アイソボリンと同時に滴下(30分早く終了する)	150 mg/m ² 250 mL	点滴静注 1.5時間

5	5-FU注250mg 5 mL 生理食塩液50mL	400 mg/m ² 50 mL	点滴静注 0.1時間
6	5-FU注250mg 5 mL 注射用水20mL	2400(-3000) mg/m ² 5-FU注と合計93 mL	中心静脈(埋込型カテーテル) バクスター LV2もしくは2day infusor使用 22時間

在宅化学療法加算1500点+携帯型ポンプ加算2500点算定可.

ナゼア, デカドロンは有害事象対策(推奨).

インフューザー使用時 時間で更新, 少量の場合残量破棄, 残量が多量の場合主治医に連絡.

終了後自己抜針.

インフューザー総量93ml=2 ml/h×46時間(92ml)+ポンプに残る量(1 ml)

(5-FU注250mg 5 mL 400mg/m²
生理食塩液50mL 50mL は生理食塩水を省きワンショット静注も可.

4. FOLFOX4療法

day 1, 2/14

注意点 血 神 消

投与順	投与薬剤	投与量	投与法
day1	1 ナゼア注0.3mg 2 mL ブドウ糖注 5 %20mL	0.3 mg 20 mL	ワンショット静脈注射
	2 デカドロン注 8 mg 2 mL ブドウ糖注 5 %100mL	8 mg 100 mL	点滴静注 0.5時間
	3 アイソボリン注25mg ブドウ糖注 5 %250mL	100 mg/m ² 250 mL	点滴静注 2 時間
	4 エルプラット注射用100mg ブドウ糖注 5 %250mL	85 mg/m ² 250 mL	点滴静注 2 時間
	3.アイソボリンと同時滴下		
	5 5-FU注250mg 5 mL 生理食塩液50mL	400 mg/m ² 50 mL	点滴静注 0.1時間
day2	6 5-FU注250mg 5 mL 注射用水20mL	600 mg/m ² 5-FU注と合計45 mL	中心静脈(埋込型カテーテル) バクスター シングルデイインフューザー使用 22時間
	1 アイソボリン注25mg ブドウ糖注 5 %250mL	100 mg/m ² 250 mL	点滴静注 2 時間
	2 5-FU注250mg 5 mL 生理食塩液50mL	400 mg/m ² 50 mL	点滴静注 0.1時間
3 5-FU注 250mg 5 mL 注射用水20mL	600 mg/m ² 5-FU注と合計45 mL	中心静脈(埋込型カテーテル) バクスター シングルデイインフューザー使用 22時間	

在宅化学療法加算1500点+携帯型ポンプ加算2500点算定可.

ナゼア, デカドロンは有害事象対策(推奨).

インフューザー使用時 時間で更新, 少量の場合残量破棄, 残量が多量の場合主治医に連絡.

終了後自己抜針.

インフューザー総量45ml=2 ml/h×22時間(44ml)+ポンプに残る量(1 ml)

(5-FU注250mg 5 mL 400mg/m²
生理食塩液50mL 50mL は生理食塩水を省きワンショット静注も可.

5. mFOLFOX6療法(FOLFOX6 LOHP100mg/m²)

day 1/14

注意点 血 神 消

投与順	投与薬剤	投与量	投与法
day1	1 ナゼア注0.3mg 2 mL ブドウ糖注 5 %20mL	0.3 mg 20 mL	ワンショット静脈注射
	2 デカドロン注 8 mg 2 mL ブドウ糖注 5 %100mL	8 mg 100 mL	点滴静注 0.5時間
	3 アイソボリン注25mg ブドウ糖注 5 %250mL	200 mg/m ² 250 mL	点滴静注 2 時間

4	エルブラット注射用 100mg ブドウ糖注 5 % 250mL 3. アイソボリンと同時滴下 交換サイクル	85(-100) mg/m ² 250 mL	点滴静注 2 時間
5	5-FU注250mg 5 mL 生理食塩液50mL	400 mg/m ² 50 mL	点滴静注 0.1時間
6	5-FU注250mg 5 mL 注射用水20mL	2400(-3000) mg/m ² 5-FU注と合計93 mL	中心静脈(埋込型カテーテル) バクスター LV2 もしくは2day infusor 使用 22時間

在宅化学療法加算1500点+携帯型ポンプ加算2500点算定可。

ナゼア, デカドロンは有害事象対策(推奨)。

インフューザー使用時 時間で更新, 少量の場合残量破棄, 残量が多量の場合主治医に連絡。

終了後自己抜針。

インフューザー総量93ml=2 ml/h×46時間(92ml)+ポンプに残る量(1 ml)

(5-FU注250mg 5 mL 400mg/m²
生理食塩液50mL 50mL は生理食塩水を省きワンショット静注も可。

6. mFOLFOX7療法 (FOLFOX7 LOHP130mg/m²)

day 1/14

注意点 血 神 消

投与順	投与薬剤	投与量	投与法
day1	1 ナゼア注0.3mg 2 mL ブドウ糖注 5 % 20mL	0.3 mg 20 mL	ワンショット静脈注射
	2 デカドロン注 8 mg 2 mL ブドウ糖注 5 % 100mL	8 mg 100 mL	点滴静注 0.5時間
	3 アイソボリン注25mg ブドウ糖注 5 % 250mL	200 mg/m ² 250 mL	点滴静注 2 時間
	4 エルブラット注射用100mg ブドウ糖注 5 % 250mL 3. アイソボリンと同時滴下 交換サイクル	100(-130) mg/m ² 250 mL	点滴静注 2 時間
	5 5-FU注250mg 5 mL 注射用水20mL	(2400-)3000 mg/m ² 5-FU注と合計93 mL	中心静脈(埋込型カテーテル) バクスター LV2 もしくは2day infusor 使用 22時間

在宅化学療法加算1500点+携帯型ポンプ加算2500点算定可。

ナゼア, デカドロンは有害事象対策(推奨)。

インフューザー使用時 時間で更新, 少量の場合残量破棄, 残量が多量の場合主治医に連絡。

終了後自己抜針。

インフューザー総量93ml=2 ml/h×46時間(92ml)+ポンプに残る量(1 ml)

FOLFOX6の5-FU注のワンショット静脈注射を無くし持続投与の5-FU注を3000mg/m²に増量(Tournigandら)

7. PEFG療法

day 1, 8, 15, 22/28(ポンプを用いた抗癌剤投与はday 1-28/28で行われる)

注意点 血 腎 消 倦

投与順	投与薬剤	投与量	投与法
day1	1 ナゼア注0.3mg 2 mL ブドウ糖注 5 % 20mL	0.3 mg 20 mL	ワンショット静脈注射
	2 デカドロン注 8 mg 2 mL ブドウ糖注 5 % 100mL	8 mg 100 mL	点滴静注 0.5時間
	3 ランダ注50mg100mL 生理食塩液500mL	40 mg/m ² 400 mL	点滴静注 2 時間 遮光
	4 ファルモルピシン注10mg 生理食塩液50mL	40 mg/m ² 50 mL	点滴静注 0.1時間
	5 ジェムザール注1000mg 生理食塩液500mL	600 mg/m ² 500 mL	点滴静注 1 時間

	6	5-FU注250mg 5 mL 注射用水100mL	1400(200×7) mg/m ² 5-FU注と合計84 mL	中心静脈持続静注(埋込型カテーテル) 168時間 バクスター 7day infuser使用
day8	1	ナゼア注0.3mg 2 mL ブドウ糖注 5 % 20mL	0.3 mg 20 mL	ワンショット静脈注射
	2	ジェムザール注1000mg 生理食塩液500mL	600 mg/m ² 500 mL	点滴静注 1 時間
	3	5-FU注250mg 5 mL 注射用水100mL	1400(20×7) mg/m ² 5-FU注と合計85 mL	中心静脈持続静注(埋込型カテーテル) 168時間 バクスター 7day infuser使用
day15, 22	1	5-FU注250mg 5 mL 注射用水100mL	1400(20×7) mg/m ² 5-FU注と合計85 mL	中心静脈持続静注(埋込型カテーテル) 168時間 バクスター 7day infuser使用

在宅化学療法加算1500点+携帯型ポンプ加算2500点算定可。
 CDDPはClイオン存在下でないと不安定となるので生理食塩水で希釈。
 アミノ酸製剤等と混注しないこと。CDDP投与中は他の薬剤を一時休止が望ましい。
 ナゼア, デカドロンは有害事象対策(推奨)。

8. S-1/CDDP療法

day 8, 9/35(S-1はday 1-21/35 内服併用)

注意点 血 腎 消

投与順	投与薬剤	投与量	投与法
day8	1	ブドウ糖注 5 % 20mL ナゼア注0.3mg 2 mL	20 mL 0.3 mg ワンショット静脈注射
	2	ヴィーン F 注500mL デカドロン注 8 mg 2 mL	500 mL 8 mg 点滴静注 2 時間
	3	生理食塩液 1 L ランダ注50mg100mL	500 mL 70 mg/m ² 点滴静注 2 時間
	4	マンニトール注20%300mL 1日1回 ランダ終了後	300 mL 点滴静注 2 時間
	5	ヴィーン F 注500mL プリンペラ10mg	500 mL 10 mg 点滴静注 2 時間
	6	ヴィーン F 注500mL	500 mL 点滴静注 2 時間
day9	1	ブドウ糖注 5 % 20mL ナゼア注0.3mg 2 mL	20 mL 0.3 mg ワンショット静脈注射
	2	ヴィーン F 注500mL デカドロン注 8 mg 2 mL	500 mL 8 mg 点滴静注 2 時間
	3	ヴィーン F 注500mL	500 mL 点滴静注 2 時間
	4	ヴィーン F 注500mL	500 mL 点滴静注 2 時間
内服	day1-21	TS-1(20mg or 25mg)	80-120 mg 分2 内服 8 時 20時

TS-1をday1-21内服併用

TS-1の量

体表面積 <1.25m² TS-1(20mg) 4Cap 80mg 分2 内服 8 時 20時
 1.25m² ≤ 体表面積 <1.50m² TS-1(25mg) 4Cap 100mg 分2 内服 8 時 20時
 1.50m² ≤ 体表面積 TS-1(20mg) 6Cap 120mg 分2 内服 8 時 20時

CDDPはClイオン存在下でないと不安定となるので生理食塩水で希釈。

アミノ酸製剤等と混注しないこと。TS-1が内服されていることを確認すること(1回量, 1日量, 服薬回数など)。

TS-1手帳(日記)の利用を勧める。

day 9は必須ではない。

9. low-dose CDDP+S-1療法

day 1, 4, 8, 11, 15, 18, 22, 25/42 (S-1はday 1-28/42 内服併用)

注意点 消 血 腎

投与順	投与薬剤	投与量	投与法
1	ランダ注10mg20mL 生理食塩液100mL	6-10 mg/m ² 100 mL	点滴静注 0.5時間
	TS-1	100 mg 分2	内服 8時20時
TS-1をday1-28内服併用			

CDDPはClイオン存在下でないと不安定となるので生理食塩水で希釈。アミノ酸製剤等と混注しないこと。

10. WHF肝動注療法

day 1, 8, 15(, 22)/28

注意点 消 倦

投与順	投与薬剤	投与量	投与法
1	5-FU注250mg 5 mL	1500 mg	肝動注(埋込型カテーテル) 動脈注射(肝動脈) 5時間
	生理食塩液250mL	220 mL	バクスター インフューザーLV50使用

在宅化学療法加算1500点+携帯型ポンプ加算2500点算定可。

週1回、増悪を確認するまで継続。休薬する際は3週1休で行うことが多い。

11. low-dose FP(LFP)療法

day 1, 4, 8, 11, 15, 18, 22, 25/35 (ポンプを用いた抗癌剤投与はday 1-28/35で行われる)

注意点 消 血

投与順	投与薬剤	投与量	投与法
day1, 8, 15, 22			
1	5-FU注250mg 5 mL	1200 mg/m ²	中心静脈持続静注(埋込型カテーテル) 168時間
	注射用水100mL	5-FU注と合計85 mL	バクスター 7 day infuser使用
2	ランダ注10mg20mL 生理食塩液100mL	6 mg/m ² 100 mL	点滴静注 0.5時間
day4, 11, 18, 25			
1	ランダ注10mg20mL 生理食塩液100mL	6 mg/m ² 100 mL	点滴静注 0.5時間

在宅化学療法加算1500点+携帯型ポンプ加算2500点算定可。

CDDPはClイオン存在下でないと不安定となるので生理食塩水で希釈。

アミノ酸製剤等と混注しないこと。CDDP投与中は他の薬剤を一時休止が望ましい。

インフューザー総量85ml=0.5ml/h×168時間(84ml)+ポンプに残る量(1ml)

12. CPT-11療法

day 1/14

注意点 血 消 倦

投与順	投与薬剤	投与量	投与法
day1 1	ブドウ糖注5%20mL	20 mL	ワンショット静脈注射
	ナゼア注0.3mg 2 mL	0.3 mg	
2	ヴィーンF注500mL	500 mL	点滴静注 2時間
	デカドロン注8 mg 2 mL	8 mg	
3	ブドウ糖注5% 500mL	500 mL	点滴静注
	トポテシン注100mg	150 mg/m ²	1.5時間

1-2は有害事象に対する前投薬(推奨)。

開始日より4-5日間CPT-11副作用対策必要。

13. CPT-11/CDDP療法

day 1(, 2,)15/28

注意点 血 腎 消 倦

投与順	投与薬剤	投与量	投与法
day1 1	ブドウ糖注 5% 20mL ナゼア注 0.3mg 2 mL	20 mL 0.3 mg	ワンショット 静脈注射
2	ヴィーン F 注 500mL デカドロン注 8 mg 2 mL	500 mL 8 mg	点滴静注 2 時間
3	ブドウ糖注 5% 500mL トポテシン注 100mg 5 mL	500 mL 70 mg/m ²	点滴静注 1.5 時間
4	生理食塩液 1L ランダ注 50mg 100mL 1 日 1 回 トポテシン終了後	500 mL 80 mg/m ²	点滴静注 2 時間 遮光
5	マンニトール注 20% 300mL 1 日 1 回 ランダ終了後	300 mL	点滴静注 2 時間
6	ヴィーン F 注 500mL 1 日 1 回	500 mL	点滴静注 2 時間
7	ヴィーン F 注 500mL 1 日 1 回	500 mL	点滴静注 2 時間
day2 1	ブドウ糖注 5% 20mL ナゼア注 0.3mg 2 mL	20 mL 0.3 mg	ワンショット 静脈注射
2	ヴィーン F 注 500mL デカドロン注 8 mg 2 mL	500 mL 8 mg	点滴静注 2 時間
3	ヴィーン F 注 500mL 1 日 1 回	500 mL	点滴静注 2 時間
4	ヴィーン F 注 500mL 1 日 1 回	500 mL	点滴静注 2 時間
day15 1	ブドウ糖注 5% 20mL ナゼア注 0.3mg 2 mL	20 mL 0.3 mg	ワンショット 静脈注射
2	ヴィーン F 注 500mL デカドロン注 8 mg 2 mL	500 mL 8 mg	点滴静注 2 時間
3	ブドウ糖注 5% 500mL トポテシン注 100mg	500 mL 70 mg/m ²	点滴静注 1.5 時間

1-2は有害事象に対する前投薬(推奨).

開始日より4-5日間制吐剤内服およびCPT-11副作用対策必要.

day2は必須ではない.

14. CPT-11/CDDP 24時間持続静注療法

day 1, 8, 15/21

注意点 血 倦

投与順	投与薬剤	投与量	投与法
1	デカドロン注 8 mg 2 mL ブドウ糖注 5% 100mL	8 mg 100 mL	点滴静注 0.5時間
2	トポテシン(カンプト)注 40mg 2 mL ランダ注 10mg 20mL 生理食塩液 50mL トポテシン(カンプト)注, ランダ注と全量 49mL	60 mg 10 mg	中心静脈(埋込型カテーテル) バクスター シングルデイインフューザー使用 24時間

1は前投薬(必ずしも必須でない).

在宅化学療法加算1500点+携帯型ポンプ加算2500点算定可.

CDDPはCPT-11との混注では活性が落ちないが, デカドロンとの混注では活性が低下するので混注しない.
インフューザー総量 49ml = 2 ml/h × 24時間 (48ml) + ポンプに残る量 (1 ml)

15. CPT-11 24時間持続静注療法

day 1, 8, 15/21

注意点 倦 血

投与順	投与薬剤	投与量	投与法
1	デカドロン注 8 mg 2 mL ブドウ糖注 5 % 100mL	8 mg 100 mL	点滴静注 0.5時間
2	トポテシン(カンプト)注40mg 2 mL 生理食塩液50mL トポテシン(カンプト)注と全量49 mL	40(-80) mg 全量49 mL	中心静脈(埋込型カテーテル) バクスター シングルデイインフューザー使用 24時間

1は前投薬(必ずしも必須でない).

在宅化学療法加算1500点+携帯型ポンプ加算2500点算定可.

インフューザー総量49ml=2 ml/h×24時間(48ml)+ポンプに残る量(1 ml)

16. weeklyPTX療法(点滴前処置)

day 1, 8, 15/21

注意点 血 脱 神

投与順	投与薬剤	投与量	投与法
1	ナゼア注0.3mg 2 mL ブドウ糖注 5 % 20mL	0.3 mg 20 mL	静注
2	ガスター注20mg ブドウ糖注 5 % 20mL	20 mg 20 mL	静注
3	ポララミン注 5 mg 1 mL ブドウ糖注 5 % 100mL	5 mg 100 mL	点滴静注 0.5時間
4	デカドロン注 8 mg 2 mL ブドウ糖注 5 % 100mL	8 mg 100 mL	点滴静注 0.5時間
5	パクリタキセル注30mg 5 mL 生理食塩液 250mL	60-80 mg/m ² 250 mL	点滴静注 専用点滴set使用 1時間

1-4はアレルギー反応などに対する前投薬(2-4は必須).

PTXは通常の点滴セットの場合、可塑剤が溶け出すので専用点滴セット使用のこと.

PTXは薬液中にアルコールを含有するため注意が必要.

17. DTX療法(前処置あり)

day 1/21

注意点 血 脱 神

投与順	投与薬剤	投与量	投与法
1	ナゼア注 0.3mg 2 mL ブドウ糖注 5 % 20mL 1日1回	0.3 mg 20 mL	静注
2	ガスター注20mg 生理食塩液20mL 1日1回	20 mg 20 mL	静注
3	ポララミン注 5 mg 1 mL ブドウ糖注 5 % 100mL 1日1回	5 mg 100 mL	点滴静注 0.5時間
4	デカドロン注 8 mg 2 mL ブドウ糖注 5 % 100mL 1日1回	8 mg 100 mL	点滴静注 0.5時間
5	ドセタキセル注80mg 2 mL<溶解液付> 生理食塩液250mL 1日1回	60 mg/m ² 250 mL	点滴静注 1時間

1-4はアレルギー反応などに対する前投薬(必ずしも必須ではない).

DTXは添付の溶解液中にアルコールを含有するため注意が必要.

18. CPT-11/LV/FU(IFL)療法

day 1, 8/21

注意点 血 脱 消 倦

投与順	投与薬剤	投与量	投与法
1	ナゼア注0.3mg 2 mL ブドウ糖注 5 %20mL	0.3 mg 20 mL	静注
2	デカドロン注 8 mg 2 mL ブドウ糖注 5 %100mL	8 mg 100 mL	点滴静注 0.5時間
3	アイソボリン注25mg 生理食塩液50mL 1日1回	10 mg/m ² 50 mL	点滴静注 0.1時間
4	5-FU注250mg 5 mL 生理食塩液50mL 1日1回	500 mg/m ² 50 mL	点滴静注 0.1時間
5	トポテシン(カンプト)注100mg 5 mL 生理食塩液250mL 1日1回	100 mg/m ² 250 mL	点滴静注 1.5時間

1-2は前投薬(必ずしも必須ではない). 骨髄抑制, 下痢などの有害事象に注意が必要.
3, 4はワンショット静注も可.

19. LV/FU(RPMI)療法

day 1, 8, 15, 22, 29, 36/56

注意点 消 倦

投与順	投与薬剤	投与量	投与法
1	ナゼア注0.3mg 2 mL ブドウ糖注 5 %20mL	0.3 mg 20 mL	静注
2	アイソボリン注 25mg KN補液3B注500mL	250 mg/m ² 500 mL	点滴静注 2時間
3	5-FU注250mg 5 mL 生理食塩液50mL	500-600 mg/m ² 50 mL	アイソボリン開始1時間後点滴静注

1は前投薬(必ずしも必須でない).

5-FU (adjuvant時 500mg/m²) で使用されることが多い.
(進行再発 600mg/m²)

3は生理食塩水を省きワンショット静注も可.

Research article

Open Access

A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

Kazuma Kobayashi*^{1,6}, Akihito Tsuji⁴, Sojiro Morita², Tadashi Horimi³, Tetsuhiko Shirasaka⁵ and Takashi Kanematsu⁶

Address: ¹Internal medicine, Clinical Oncology Group, Kochi Municipal Central Hospital, Kochi, Japan, ²Radiology, Clinical Oncology Group, Kochi Municipal Central Hospital, Kochi, Japan, ³Surgery, Clinical Oncology Group, Kochi Municipal Central Hospital, Kochi, Japan, ⁴Department of Clinical Oncology, Kochi Health Science Center, Kochi, Japan, ⁵Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan and ⁶Department of Transplantation and Digestive Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Email: Kazuma Kobayashi* - bakehasky@eagle.ocn.ne.jp; Akihito Tsuji - a-tsuji@r4.dion.ne.jp; Sojiro Morita - sojiro@mxp.mesh.ne.jp; Tadashi Horimi - horimi@kcan.ne.jp; Tetsuhiko Shirasaka - t-shirasaka@taiho.co.jp; Takashi Kanematsu - kanematsu@net.nagasaki-u.ac.jp

* Corresponding author

Published: 06 May 2006

Received: 02 October 2005

BMC Cancer 2006, 6:121 doi:10.1186/1471-2407-6-121

Accepted: 06 May 2006

This article is available from: <http://www.biomedcentral.com/1471-2407/6/121>

© 2006 Kobayashi et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Unresectable biliary tract carcinoma is known to demonstrate a poor prognosis. We conducted a single arm phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) for advanced biliary tract malignancies basically on an outpatient basis.

Methods: Between February 1996 and September 2003, 42 patients were enrolled in this trial.

LFP therapy: By using a total implanted CV-catheter system, 5-FU (160 mg/m²/day) was continuously infused over 24 hours for 7 consecutive days and CDDP (6 mg/m²/day) was infused for 30 minutes twice a week as one cycle. The administration schedule consisted of 4 cycles as one course. RESIST criteria (Response evaluation criteria for solid tumors) and NCI-CTC (National Cancer Institute-Common Toxicity Criteria) (ver.3.0) were used for evaluation of this therapy. The median survival time (MST) and median time to treatment failure (TTF) were calculated by the Kaplan-Meier method.

Results: Patients characteristics were: mean age 66.5(47–79); male 24 (54%); BDca (bile duct carcinoma) 27 GBca (Gallbladder carcinoma) 15; locally advanced 26, postoperative recurrence 16. The most common toxicity was anemia (26.2%). Neither any treatment related death nor grade 4 toxicity occurred. The median number of courses of LFP Therapy which patients could receive was two (1–14). All the patients are evaluable for effects with an over all response rates of 42.9% (95% confidence interval C.I.: 27.7–59.0) (0 CR, 18 PR, 13 NC, 11 PD). There was no significant difference regarding the anti tumor effects against both malignant neoplasms. Figure 2 Shows the BDca a longer MST and TTF than did GBca (234 vs 150, 117 vs 85, respectively), but neither difference was statistically significant.

The estimated MST and median TTF were 225 and 107 days, respectively. The BDca had a longer MST and TTF than GBca (234 vs 150, 117 vs 85, respectively), but neither difference was statistically significant.

Conclusion: LFP therapy appears to be useful modality for the clinical management of advanced biliary tract malignancy.

Background

Biliary tract cancers are rare in North America, with approximately 8,000 new cases diagnosed in 2003 [1]. However, bile duct carcinoma (BDca) and gallbladder carcinoma (GBca) are not rare in northern Japan [2], Taiwan [3], and South Korea [4]. In Japan, these malignancies are the sixth leading cause of cancer deaths, and in 1999, there were 8,557 deaths from BDca and 6,340 deaths from GBca [5]. As a surgical resection of the primary tumor and the areas of local extension remains the most effective therapy [6], even for non-curative operations [7]. However, in over 75% of the patients whose disease is locally advanced or already metastatic cases, the median survival time for patients receiving only the best possible supportive care is only about 6 months [1]. Furthermore, there is a high rate of both local and systemic recurrence, even after a curative resection [1,6]. As a result, an effective chemotherapy for biliary malignancy has been eagerly awaited. However, systemic single-agent chemotherapy has so far shown a poor efficacy [6,8], though many efforts have been done [9]. For example, the response rate of 5-fluorouracil (5-FU), cisplatin (CDDP), was 10–13%, and 8%, respectively [4], while new chemotherapeutic agents CPT-11, Gemcitabine, showed the poor response rate of 12.5% and 8%, respectively [3,4,10].

As a result, an effective combination chemotherapy has been eagerly anticipated. We spotlighted the combination of the two old anti-cancer agents, 5-FU, and CDDP.

In Japan, FP therapy combination of 5-FU continuous venous infusion (CVI) and low-dose consecutive CDDP (LFP) Therapy has been widely used since early 1990s for gastrointestinal advanced cancer [11,12]. Because of its low toxicity and relatively high response rate [13], LFP therapy has been widely used for the treatment of various unresectable advanced solid tumors, such as gastric cancer [14], hepatocellular carcinoma [15], pancreatic cancer [12], colon and head and neck [11]. Recent findings in experimental models have shown an additive or synergistic antitumor effects of LFP therapy. We observed that CDDP inhibited methionine transport into tumor cells, both in vitro and in vivo, with a synergic interaction by CDDP functioning as a modulator of 5-FU [11,12]. This synergistic effect was also associated with the induction of apoptosis [16] and the p53 pathway [17,18].

Based on these findings, we conducted a single arm phase II study of LFP therapy in patients with advanced BDca and GBca.

Methods

Eligibility criteria

This study protocol was approved by the Kochi Municipal Central Hospital, Japan and written informed consent was

obtained from all the patients. The patients were required to have unresectable locally advanced or metastatic disease of the biliary-tract or gallbladder advanced carcinoma with measurable lesions on a computed tomography (CT) scan. Other eligibility criteria included an age 18 years or more, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, estimated life expectancy of 12 weeks or more, adequate bone marrow function (leukocyte count > 3,500/ μ l, neutrophil count > 1,500/ μ l, and platelet count > 100,000/ μ l), bilirubin < 5.0 mg/dl, transaminases and alkaline phosphatase < 6 times upper limit of normal, and normal renal function tests (creatinine level < 1.5 mg/dl, or creatinine clearance > 60 ml/min). No previous chemotherapy was permitted within 2 weeks. Radiotherapy and stenting to decompress the biliary tract was permitted. Patients with other clinically significant laboratory abnormalities, uncontrolled infection, concurrent severe medical problems unrelated to malignancy that would expose the patient to extreme risk, patients receiving another investigational drug within 30 days prior to study or receiving concurrent hormonal therapy, immunotherapy and those pregnant or lactating were excluded from the study. The study was conducted according to the Good Clinical Practices and the Declaration of Helsinki as amended in Hong Kong (1989).

Treatment plans

All patients were admitted to the hospital for about 10 days for a pretreatment evaluation, the first cycle treatment, and observation for adverse effects. If the degree of toxicity was within Grade 0–2, a second cycle of treatment or more were continued on an outpatient basis.

A pretreatment evaluation included complete medical history, physical examination, evaluation of performance status, urinalysis, chest radiograph, and diagnostic studies assessment such as CT scan. When the patient meets the eligibility criteria, central venous catheter system with a heparin coated catheter (Anthon PU catheter; TORAY™ and a port (Celcite brachial; TORAY™ or Vital port mini; COOK™) is implanted according to the method of Hata et al [19] prior to treatment.

The treatment plan involved the administration of 5-FU (160 mg/m²/day) was continuously infused over 24 hours using a disposable infusion pump (7-day Infuser; Baxter™) and CDDP (3–6 mg/m²/day) diluted with normal saline was infused for half an hour. Hydration was not needed. These doses were determined based on our experience of the previous LFP therapy for hepatocellular carcinoma [15]. The administration schedule consisted of 5-FU for 7 consecutive days and CDDP twice a week (day 1 and day 4) for each of four weeks as one treatment course. The treatment schedule and CV catheter system was

depicted on figure 1. Unless an exacerbation of the symptoms was observed, multiple courses of treatment were administered. When more than a grade 3 adverse effect was observed, a CDDP infusion was omitted and observed. If this omission was ineffective, 5-FU was also omitted. In case of hemoglobin < 8.0 g/dl, platelet count < 50,000/ μ l neutrophil count < 1,000/ μ l, blood transfusion of concentrated red blood cells (RBCs) or platelets, or granulocyte-stimulating factor (G-CSF) was applied.

We do not increase the dose of the anti-cancer agent during the chemotherapy protocol, even if the toxicity is low.

Toxicity and response evaluation

Complete blood counts twice a week and biochemical examinations were weekly carried out. Toxicity was evaluated based on the National Cancer Institute Common Toxicity Criteria (NCI-CTC) ver.3. The response was clas-

sified based on the Response Evaluation Criteria in Solid Tumors Guidelines (RECIST criteria) [20], taking into account the measurement of the longest diameter only for all target lesions: complete response (CR)-the disappearance of all target lesions; partial response (PR)-at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter; progressive disease (PD) -at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions; no change (NC)-neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started. Patients with a CR, a PR, an NC, or a PD required a confirmatory disease assessment at least one

Figure 1. *Schedule for treatment and infusional method*




Figure 1 *Schedule for treatment and infusional method.* A schematic drawing of the chemotherapy schedule (a), and the Central Venous catheter system consists of PAS port (b), implantation technique (c) and portable infusion pump (d).

Figure 2. Survival and Treatment failure




Figure 2 *Survival and Treatment failure.* Kaplan-Meier curves of Overall Survival (upper column) and Time to treatment failure (TTF) (lower column) are shown.

month later. Target lesions were evaluated by a plain and enhanced CT scan and plain chest X-ray for each course.

Statistical analyses

We used the Stat View J 5.0 software package (Abacus Concepts, Stat View. Abacus Concepts, Inc., Berkeley, CA, 1992-1998) for the statistical analysis. The time to Treatment Failure and the overall Survival Cumulative were obtained by the Kaplan-Meier method. The disease-free survival was compared by the Log rank test among the groups. Prognostic variables were evaluated by Cox's multivariate proportional hazard model. We defined the risk factors for LFP therapy for biliary tract malignancies in our study as significant factors based on both the Cox's and Kaplan-Meier's. A p value of less than 0.05 was considered to be statistically significant.

Results

Patient characteristics

From February 1996 to December 2003, 42 patients were enrolled into the present study, and all were evaluable for efficacy and toxicity analyses. They consisted of 24 males and 18 females. The mean age was 66.5(47-79). The number of patients with BDca and GBca were 27 and 15, respectively. Twenty-six patients who were initially diagnosed to have biliary tract malignancies were not eligible for surgery because of locally advanced disease and/or metastasis (locally advanced). Another 16 patients had local recurrence and/or distant metastasis after surgery (postoperative recurrence). Disease extension was such that 11 patients (BDca: 7, GBca: 4), had only primary or local recurrence patients had only metastatic disease (BDca: 9, GBca: 5), another 17 patients (BDca:11, GBca: 6) had both diseases. Four patients had previously undergone

Table 1: Patient Characteristics

Variables	Stratification	Over all	BDca	GBca
Species of cancer		42	27	15
Sex	(male/female)	(24/18)	(17/10)	(7/8)
Age		66.5 ± 7.5	64.8 ± 8.2	69.5 ± 4.7
ECOG PS	(0/1/2)	(36/4/2)	(22/4/1)	(14/0/1)
Disease Status	(unresectable/postoperative recurrence)	(26/16)	(15/12)	(11/4)
Disease extension	locally advanced (primary)	26	15	11
	local recurrence	7	7	0
	liver metastasis	9	4	5
	lung metastasis	4	3	1
	lymphnode metastasis	11	4	7
	miscellaneous metastasis	5	5	0
Tumor marker	carcinoembryonic antigen (CEA)	16.7 ± 60.7	6.4 ± 17.2	36.7 ± 100.5
	CA19-9	3035.5 ± 9507.6	4495.3 ± 11688.8	407.9 ± 587.2
Previous chemotherapy	(yes/no)	(4/38)	(3/24)	(1/14)

Abbreviations

BDca: bile duct carcinoma, GBca: Gallbladder carcinoma, ECOG PS: Eastern Cooperative Oncology Group performance status

chemotherapy, including such treatments as CDDP + VP-16, 5-FU + mitomycin C + farmorubicin, adriamycin + 5-FU. Two of 4 patients experienced surgery before these chemotherapy (i.e. postoperative recurrence). Seven of BDca patients had palliative radiotherapy. Three of these seven underwent surgery before radiation (i.e. postoperative recurrence). There were some differences between BDca and GBca on age, and serum tumor marker levels (CEA and CA19-9), but neither was statistically significant. The patient characteristics are enumerated in Table 1.

Response and time-to-event measures

The overall response rate (RR) was 42.9% (95% confidence interval C.I.: 27.7–59.0) with CR 0, PR 18, NC 13, PD 11, and clinical benefit was 73.8% (95% C.I.: 58.0–86.2). Patients with a PR, an NC or a PD required a confirmatory disease assessment at least two months later.

One GBca patient who got PR, could receive curative resection. The RR of primary lesion or locally advanced lesion was 50.0% (95% C.I.: 30.6–69.4), and the RR of

Table 2: Anti tumor effect

Over all						
	CR	PR	NC	PD	Response Rate (%)95%C.I. CR+PR/TOTAL	Clinical Response (%)95%C.I. CR+PR+NC/TOTAL
Over all	0	18	13	11	42.9 (27.7–59.0)	73.8 (58.0–86.2)
BDca	0	11	10	6	40.7 (22.4–61.2)	77.8 (57.8–91.4)
GBca	0	7	3	5	46.7 (21.1–73.5)	66.7 (38.4–88.2)
Primary or local recurrence						
	CR	PR	NC	PD	Response Rate (%)95%C.I. CR+PR/TOTAL	Clinical Response (%)95%C.I. CR+PR+NC/TOTAL
Over all	0	14	8	6	50.0 (30.6–69.4)	78.6 (59.0–91.7)
BDca	0	9	6	3	50.0 (26.0–74.0)	83.3 (58.6–96.5)
GBca	0	5	2	3	50.0 (18.6–81.4)	70.0 (34.7–93.5)
Metastatic lesion						
	CR	PR	NC	PD	Response Rate (%)95%C.I. CR+PR/TOTAL	Clinical Response (%)95%C.I. CR+PR+NC/TOTAL
Over all	0	10	12	9	32.3 (16.7–51.4)	71.0 (52.0–85.8)
BDca	0	6	9	5	30.0 (11.8–54.3)	75.0 (50.9–91.4)
GBca	0	4	3	4	36.4 (10.8–69.3)	66.7 (30.7–89.2)

Abbreviations

BDca: bile duct carcinoma, GBca: Gallbladder carcinoma

Table 3: Toxicity

Hematological Toxicity	Gr1	Gr2	Gr3	Gr4	≥Gr3 (%)	Over all (%)
anemia	0	11	0	0	0 (0)	11 (26.2)
leukopenia	0	1	0	0	1 (0)	1 (2.3)
thrombocytopenia	0	2	3	0	3 (7.1)	5 (11.9)
Non-hematological Toxicity	Gr1	Gr2	Gr3	Gr4	≥Gr3 (%)	Over all (%)
nausea	3	4	1	0	1 (2.3)	8 (19.0)
vomiting	1	1	3	0	1 (2.3)	5 (11.9)
appetite loss	0	0	6	0	6 (14.3)	6 (14.3)
oral mucositis	0	4	0	0	0 (0)	4 (9.5)
taste disturbance	0	1	0	0	1 (2.3)	1 (2.3)
upper GI tract bleeding	0	1	0	0	0 (0)	1 (2.3)
diarrhea	1	0	0	0	0 (0)	1 (2.3)
general fatigue	0	1	1	0	1 (2.3)	2 (4.7)
jaundice	0	0	4	0	4 (9.5)	4 (9.5)
serum AST/ALT level elevation	0	4	1	0	1 (2.3)	1 (2.3)
Serum creatinine level elevation	0	6	0	0	0 (0)	6 (14.3)

metastatic lesions was 32.3%. Various RRs were demonstrated in Table 2. The responses of metastatic lesions were as such; liver (CR:0, PR:6, NC:0, PD:3), lung (CR:0, PR:1, NC:3, PD:0), lymph node (CR:0, PR:3, NC: 6, PD2), miscellaneous (CR:0, PR: 2, NC: 2, PD: 1). There was no significant difference in terms of anti tumor effects against both malignant neoplasms. The overall MST was 225 days. The median TTF was 107 days. Figure 2 Shows the BDca a longer MST and TTF than did GBca (234 vs 150, 117 vs 85, respectively), but neither difference was statistically significant.

Toxicity

As shown in Table 3, neither any treatment related death nor grade 4 toxicity occurred. Overall, the most common

toxicity was anemia occurring in 26.2% of patients followed by nausea (19.0%). The most frequent grade 3 toxicity was appetite loss (14.3%). The occurrence of ascites and jaundice may be partly because of the outcome of the disease progression.

Prognostic factors related survival and TTF

An analysis of a Cox proportional hazard model showed that no significant factor was found prognostic factors for either the overall survival or TTF (Table 4). However, the patients with LFP courses ≥ 2 had both a longer overall survival and TTF than those with LFP courses < 2 as depicted in Figure 3. The distribution of the patients with LFP courses ≥ 2 was (PR/NC/PD = 16/8/3), while that of those with LFP courses ≤ 2 was (PR/NC/PD = 2/5/8).

Table 4: Prognostic factors for over all survival and TTF

Stratification	Over all survival Time to treatment Failure					
	Hazard ratio	p-value	95% C.I.	Hazard ratio	p-value	95% C.I.
Sex (male/female)	0.123	0.0128	0.024-0.640	0.225	0.0095	0.073-0.695
Age (≥ 69 / < 69)	0.634	0.6082	0.111-3.692	2.380	0.2269	0.583-9.713
ECOG PS (PS0/PS1/PS2)	0.016	0.0015	0.001-0.259	0.230	0.0007	0.001-0.152
Species of tumor (BDca/GBca)	0.095	0.0198	0.013-0.688	0.001	0.0411	0.0856-0.943
Disease status (locally advanced/postoperative recurrence)	0.121	0.0179	0.021-0.695	0.802	0.7388	0.001-0.152
Radiation (yes/no)	8.369	0.1491	0.467-150.112	0.603	0.4586	0.158-2.299
Previous chemotherapy (yes/no)	0.143	0.0255	0.016-1.241	0.495	0.4086	0.094-2.622
Initial CEA level (≥ 1 UL/ < 1 UL)	1.098	0.9053	0.234-5.160	2.453	0.1267	0.775-7.763
Interval decreasing CEA level (yes/no)	0.224	0.2859	0.014-3.499	1.734	0.5968	0.260-11.568
Initial CA19-9 level (≥ 5 UL/ < 5 UL)	0.078	0.0255	0.014-3.499	1.734	0.5968	0.260-11.568
Interval decreasing CA19-9 level(yes/no)	1.449	0.7667	0.125-16.774	0.326	0.2600	0.047-2.290

(Cox proportional hazard model)

Abbreviations

BDca: bile duct carcinoma, GBca: Gallbladder carcinoma, ECOG PS: Eastern Cooperative Oncology Group performance status, CEA: carcinoembryonic antigen, UL: upper limit

Figure 3. Relation between number of LFP courses and Over all survival and TTF




Figure 3
 Relation between number of LFP courses and Over all survival and TTF. Differences by accomplished LFP (5-FU (5-fluorourasil) continuous infusion and Low-Dose Consecutive Cisplatin(CDDP)) courses are depicted regarding the overall Survival (upper column) and Time to treatment failure (TTF)(lower column).

Cost benefit

The difference between the inpatient-basis and the outpatient-basis or home treatment of this therapy in respect to cost is shown in Table 5. This was calculated based on the assumption that one patient received one-month treatment of this LFP therapy covered by Japanese National Health Insurance. The cost for outpatient-basis/home LFP therapy was approximately equivalent to 996 U.S. dollars which was about one-sixth less than the cost on an inpatient-basis.

Discussion

In the present study, we achieved an RR of 42.9% (95% C.I.: 27.7-59.0) with a median over all survival of 225 days and median TTF of 107 days. No grade 4 toxicity or treatment related death occurred. The cause of treatment

failure of the other 37 patients was an aggravation of general condition due to primary disease, and not due to any adverse effect. LFP therapy showed a good compliance and the adverse effects were either tolerable or controllable.

The overall response rate of our study is relatively high for this type of tumor. However, our LFP method has achieved more than a 50% overall response rate in other tumors such as esophageal, gastric or colon cancers. Biliary tract cancer may be more malignant than other types of cancer.

One cycle of conventional LFP therapy consists of CDDP infusion consecutive five days per week and 24 hr continuous infusion of 5-FU consecutively 7 days per week [14].

Table 5: Cost-benefit

Outpatient-basis or home	Inpatient-basis
At home malignant tumor Administration fee 25,000 yen	Basic admission fee 472,900 yen Local infusion technical fee (addition to minute infusion) 46,200 yen
Portable infuser pump using fee 15,000 yen	Diet 63,600 yen
Medication CDDP 20,000 yen 5-FU 15,000 yen	Medication CDDP 20,000 yen 5-FU 15,000 yen
Tumor marker 5,000 yen	Tumor marker 5,000 yen
Other laboratory test 8,400 yen	Other laboratory test 8,400 yen
Imaging diagnosis 15,000 yen (antiemetic drug 16,000 yen)	Imaging diagnosis 15,000 yen (antiemetic drug 16,000 yen)
Total 103,600 (119,600) yen	Total 646,300 (662,300) yen

(One month treatment covered by Japanese National Health Insurance, A U.S. dollar is approximately equivalent to 104 Japanese yen)

Therefore, the patients were obliged to receive inpatient-basis treatment, which led to their inconvenience and a heavy burden due to the high admission fee. Regarding the five consecutive days of CDDP infusion, our preliminary study showed that CDDP infusion twice a week was sufficient to maintain the blood concentration of CDDP in order to achieve synergistic effect [15]. This fact and the application of a CV catheter system with PAS or vital port and portable infusion pump thus enable the patients to receive outpatient-basis treatment which is equivalent to the inpatient treatment in quality. As for central venous catheter, Knox reported six catheter infection cases occurred in 27 patients [6], but no complications related to the catheter system occurred in our study. Our good results were due to the easy technique of implantation

associated with the catheter system [19]. In our hospital from July 1994 to December 2002, infection related to the CV-catheter system occurred in only 44 cases of total 1,350 implanted patients (3.4%).

We herein tried to compare our regimen with other combination chemotherapies [2,4-6,21-23] are summarized in Table 6. Our combination chemotherapy is thus considered to be effective enough to be recommended the biliary tract malignancy since our study achieved a low toxicity and high efficacy with a relatively higher RR and longer MST in comparison to these regimens. Kim's regimen [4] is also interesting since oral capecitabine was used. However, our results showed higher response rate and lower toxicity than Kim's.

Table 6: Current Combination Chemotherapy for Biliary tract cancer

Author (published year)	Number of Patients	Species of cancer	Regimen	RR (%)	MST (days)	mTTF (days)	Adverse effects (\geq Gr3)	Treatment related death
Ishii(2004)	21	GBca	CEF(CDDP/5-FU/epirubicin)	33.3	177*	-	hematological toxicity (52.3%)	none
	25	GBca	FAM(5-FU/Doxorubicin/Mitomycin)	7.1		-	hematological toxicity (20%)	none
Lee (2004)	4	BDca	Gemcitabine/CDDP	50	270	150	thrombocytopenia (75%)	none
Doval(2004)	30	GBca	Gemcitabine/CDDP	36.6	140	126	nausea/vomiting (16%)	2
Malik(2003)	11	GBca	Gemcitabine/CDDP	64	294	196	anemia (45%)	none
Knox (2004)	27	BDca/ CBca	Gemcitabine/5-FU	33	159	111	hematological toxicity (11%)	none
Malik(2003)	30	CBca	Leucovorin/5-FU	7.5	444	141	diarrhea (30%)	1
Kim (2003)	42	BDca/ CBca	Capecitabine/CDDP	21.4	273	111	leucopenia (20%)	none

(* The result was overall survival of combined CEF and FAM)

Abbreviations

BDca: bile duct carcinoma, GBca: Gallbladder carcinoma, CDDP: Cisplatin, 5-FU: 5-fluorourasil, RR: response rate, MST: median survival time, mTTF: median time to treatment failure

One of the problems of our study was that the prognosis of the patients receiving less than two courses of LFP was remarkably poor as shown in Figure 3. Of these patients only one could receive second-line chemotherapy with CDDP/CPT-11. It is important to predict whether LFP therapy is effective or not. Fortunately, an effective method for predicting LFP therapy effectiveness for gastrointestinal cancers by detecting p53 has been reported [16-18]. This method may be applicable for biliary tract malignancy.

The present study used 5-FU continuous venous infusion (CVI) as an effector. If an oral drug which can help maintain a high blood concentration of 5-FU equivalent to or higher than that for the CVI-method exist, then the patients with biliary tract malignancy can avoid the need to use the catheter system but while still achieving an improved anti-tumor effect thus leading to an advanced quality of life. S-1 invented by one of the authors (T.S) [11] can thus be one of the candidates for this aim. S-1 is a novel oral fluoropyrimidine that consists of tegafur, which is a prodrug of 5-FU, 5-chloro-2, 4-dihydroxypyrimidine, which inhibits dihydropyrimidine dehydrogenase activity and potassium oxonate, which reduces gastrointestinal toxicity [11,24]. This feature helps to maintain a high blood concentration of 5-FU and less toxicity of digestive tract [11,24]. The result of 101 advanced gastric cancer patients with S-1 was reported to be 44.6% RR with 244 days of MST [25,26]. Furthermore, using the synergistic effect of LFP, the combination chemotherapy of CDDP and S-1 has also been performed for gastric cancer or pancreatic cancer at some institutes [13,25,27-30]. Many reports have so far described promising results. The application of low-dose CDDP and S-1 for biliary malignancies at our institute is now under consideration. Our study of LFP is thus considered to support the use of low-dose CDDP and S-1 regimen for BDca and GBca.

Conclusion

In conclusion, this outpatient-basis LFP therapy is considered to be appropriate as a first-line treatment for either advanced or recurrent biliary tract cancer and it promises to help improve the quality of life of cancer patients while also facilitating the clinical management of such patients.

Competing interests

The authors declares that they have no competing interests.

Authors' contributions

KK carried out this study, and drafted this manuscript. AT conceived the design of present study. SM participated in assessing radiological findings. TH participated in its design and coordination. TS participated in the pharmacological basis of the study. TK participated in the coordi-

nation of this study and instructed the collaborators of this manuscript.

Acknowledgements

We appreciated Ms Ito Kawamura for gathering and preparing data for this study. And also we thanked Dr Brian Quinn for grammatical check for our manuscripts.

This study could be performed as ordinary clinical practice, therefore the cost of this study was covered by National or other insurance. Any special funds were not needed.

References

- Bhargava R, Jani CR, Savarese DMF, O'donell JL, Stuart KE, Lim CMR: **Gemcitabine and Irinotecan in Locally Advanced or Metastatic Biliary Cancer: Preliminary Report.** *Oncology* 2003, **17**:23-26.
- Malik IA, Aziz Z, Zaidi SHM, Sethuraman G: **Gemcitabine and Cisplatin Is a Highly Effective Combination Chemotherapy in Patients With Advanced Cancer of the Gallbladder.** *Am J Clin Oncol* 2003, **26**:174-177.
- Lin MH, Chen JS, Chen HHW, Su WC: **A Phase II Trial of Gemcitabine in the Treatment of Advanced Bile Duct and Periapillary Carcinomas.** *Chemotherapy* 2003, **49**:154-158.
- Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK: **Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer.** *Ann Oncol* 2003, **14**:1115-1120.
- Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M, Tosiya Sato: **Chemotherapy in the Treatment of Advanced Gallbladder Cancer.** *Oncology* 2004, **66**:138-142.
- Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ: **Gemcitabine concurrent with continuous infusion 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.** *Ann Oncol* 2004, **15**:770-774.
- Ishikawa T, Horimi T, Shima Y, Okabayashi T, Nishioka Y, Hamada M, Ishikawa J, Tsuji A, Takamatsu M, Morita S: **Evaluation of aggressive surgical treatment for advanced carcinoma of the gallbladder.** *J Hepatobiliary Pancreat Surg* 2003, **10**:233-238.
- Hejna M, Zielinski CC: **Nonsurgical management of gallbladder cancer: cytotoxic treatment and radiotherapy.** *Expert Rev Anticancer Ther* 2001, **1**:291-300.
- Todoroki T: **Chemotherapy for Gallbladder Carcinoma-A Surgeon's Perspective.** *Hepato-Gastroenterology* 2000, **47**:948-955.
- Alberts SR, Fishkin PA, Burgart LJ, Cera PJ, Mahoney MR, Morton RF, Johnson PA, Nair S, Goldberg RM: **CPT-11 for Bile-Duct and Gallbladder Carcinoma. A Phase II North Central Cancer Treatment Group (NCCTG) Study.** *Int J Gastrointestinal Cancer* 2002, **32**:107-111.
- Shirasaka T, Yamamitsu S, Tsuji A, Taguchi T: **Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.** *Invest New Drugs* 2000, **18**:315-329.
- Hirata K, Mukaiya M, Yamamitsu S, Oikawa I, Takashima T, Katsuramaki T, Sasaki K, Denno R, Shirasaka T: **Biochemical modulation therapy for pancreatic cancer.** *J Hepatobiliary Pancreat Surg* 1998, **5**:255-260.
- Tanaka B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T, Hirakawa K: **Combination Phase I trial of a Novel Oral Fluorouracil Derivative S-1 with Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902).** *Clin Cancer Res* 2004, **10**:1664-1669.
- Enjoji A, the Nagasaki Digestive Organ Cancer Chemotherapy Study-Group Japan: **Combination chemotherapy of 5-fluorouracil and low-dose cisplatin in advanced and recurrent gastric cancer: a multicenter retrospective study in Nagasaki, Japan.** *Anticancer Res* 2002, **22**:1135-1139.
- Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K, Tanimoto M: **Combination Chemotherapy with Continuous 5-Fluorouracil and Low-dose Cisplatin Infusion for Advanced Hepatocellular Carcinoma.** *Anticancer Res* 2003, **23**:1891-1898.

16. Mori S, Kunieda K, Sugiyama Y, Saji S: **Prediction of 5-fluorouracil and cisplatin synergism for advanced gastrointestinal cancers using a collagen gel droplet embedded culture.** *Surg Today* 2003, **33**:577-583.
17. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S: **Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel.** *Int J Oncol* 2004, **24**:807-813.
18. Nakata B, Chung KH-YS, Ogawa M, Ogawa Y, Yanagawa K, Mugeruma K, Inoue T, Yamashita Y, Onoda N, Maeda K, Sawada T, Sowa M: **p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer.** *Surg Today* 1998, **28**:595-598.
19. Hata Y, Morita S, Morita Y, Awatani T, Takasaki M, Horimi T, Zen Ozawa: **Peripheral Insertion of a Central Venous Access Device Under Fluoroscopic Guidance Using a Peripherally Accessed System (PAS) Port in the Forearm.** *Cardiovasc Intervent Radiol* 1998, **21**:230-233.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, Oosterom ATV, Christian MC, Gwyther SG: **New Guidelines to Evaluate the Response to Treatment in Solid Tumors.** *J Natl Cancer Inst* 2000, **92**:205-216.
21. Lee MA, Woo IS, Kang JH, Hong YS, Lee KS: **Gemcitabine and Cisplatin Combination Chemotherapy in Intrahepatic Cholangiocarcinoma as Second-line Treatment: Report of Four Cases.** *Jpn J Clin Oncol* 2004, **34**:547-550.
22. Malik IA, Aziz Z: **Prospective Evaluation of Efficacy and Toxicity of 5-FU and Folinic Acid (Mayo Clinic Regimen) in Patients With Advanced Cancer of the Gallbladder.** *Am J Clin Oncol* 2003, **26**:124-126.
23. Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla YK, Gupta S, Awasthy BS: **A Phase II study of gemcitabine and cisplatin in chemotherapy-naïve, unresectable gallbladder cancer.** *Br J Cancer* 2004, **90**:1516-1520.
24. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T: **Pharmacokinetic Study of S-1, a Novel Oral Fluorouracil Antitumor Drug.** *Clin Cancer Res* 1999, **5**:2000-2005.
25. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagasima F, Shirano K, Matsumura Y, Goto M: **Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer.** *Br J Cancer* 2003, **89**:2207-2212.
26. Maehara Y: **S-1 in gastric cancer; a comprehensive review.** *Gastric Cancer* 2003, **6**:2-8.
27. Hyodo I, Nishina T, Moriwaki T, Endo S, Terao T, Hirao K, Nasu J, Hirasaki S, Endo H, Masumoto T, Tajiri H, Kurita A: **A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting.** *Eur J Cancer* 2003, **39**:2328-2333.
28. Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S: **Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer.** *Gastric Cancer* 2003, **6**:45-49.
29. Tsujitani S, Fukuda K, Nobuyuki Kaibara N: **Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.** *Gastric Cancer* 2003, **6**:50-57.
30. Hayashi K, Imaizumi T, Kazumi Uchida, Kuramochi H, Takasaki K: **High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.** *Oncology Reports* 2002, **9**:1355-1361.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2407/6/121/prepub>

Publish with **Bio Med Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:

http://www.biomedcentral.com/info/publishing_adv.asp

